OptimizeRx (OPRX) Projected to Post Quarterly Earnings on Thursday

by · The Cerbat Gem

OptimizeRx (NASDAQ:OPRX – Get Free Report) is expected to announce its Q4 2025 results after the market closes on Thursday, March 5th. Analysts expect the company to announce earnings of $0.23 per share and revenue of $30.9150 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 5, 2026 at 4:30 PM ET.

OptimizeRx Trading Down 2.5%

Shares of NASDAQ:OPRX opened at $7.39 on Tuesday. The firm has a market cap of $137.75 million, a price-to-earnings ratio of 18.95 and a beta of 1.21. OptimizeRx has a 12 month low of $3.99 and a 12 month high of $22.25. The company’s fifty day simple moving average is $10.94 and its 200 day simple moving average is $14.97. The company has a quick ratio of 3.05, a current ratio of 3.05 and a debt-to-equity ratio of 0.20.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on OPRX. Citizens Jmp boosted their price target on OptimizeRx from $23.00 to $24.00 and gave the company a “market outperform” rating in a report on Friday, November 7th. Wall Street Zen raised OptimizeRx from a “buy” rating to a “strong-buy” rating in a research report on Sunday, December 14th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of OptimizeRx in a research report on Monday, December 22nd. Stephens decreased their price target on shares of OptimizeRx from $20.00 to $17.00 and set an “equal weight” rating for the company in a research note on Monday, November 17th. Finally, Zacks Research downgraded shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a report on Monday, December 15th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, OptimizeRx presently has a consensus rating of “Moderate Buy” and an average target price of $20.50.

Get Our Latest Analysis on OptimizeRx

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of OptimizeRx by 15.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,059,109 shares of the company’s stock valued at $21,712,000 after buying an additional 138,224 shares during the last quarter. Kennedy Capital Management LLC increased its holdings in OptimizeRx by 42.8% during the third quarter. Kennedy Capital Management LLC now owns 674,918 shares of the company’s stock worth $13,836,000 after buying an additional 202,446 shares during the last quarter. Parkman Healthcare Partners LLC raised its position in OptimizeRx by 0.4% during the third quarter. Parkman Healthcare Partners LLC now owns 509,611 shares of the company’s stock worth $10,447,000 after acquiring an additional 2,188 shares in the last quarter. State Street Corp raised its position in OptimizeRx by 21.6% during the fourth quarter. State Street Corp now owns 477,531 shares of the company’s stock worth $5,855,000 after acquiring an additional 84,808 shares in the last quarter. Finally, Manatuck Hill Partners LLC lifted its stake in OptimizeRx by 3.8% in the third quarter. Manatuck Hill Partners LLC now owns 472,307 shares of the company’s stock valued at $9,682,000 after acquiring an additional 17,307 shares during the last quarter. Institutional investors and hedge funds own 76.47% of the company’s stock.

OptimizeRx Company Profile

(Get Free Report)

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.

Featured Articles